AstraZeneca, in a move to boost its cancer treatment pipeline, said Tuesday it has entered into an agreement to acquire TeneoTwo for up to $1.27 billion.
TeneoTwo's lead drug candidate, TNB-486, is being developed in early-stage clinical testing as a potential treatment for relapsed and refractory B-cell non-Hodgkin's lymphoma, a type of cancer that starts in the white blood cells.
One of AstraZeneca' s leading products, Calquence, generated sales of more than $1.2 billion for the company last…
